Search Results

Deadline September 27, 2023 GPCR Events, Meetings, and Webinars October 2 - 3, 2023 | Celebrating Robert J.

: Allosteric Function and Biased Signaling" at the DOT NEW October 2 - 3, 2023 | Celebrating Robert J.

Nichola J Smith's investigation: Gene expression of TAS1R taste receptors for cardiometabolic disease

work on Conformational dynamics underlying atypical chemokine receptor 3 activation Michael Trogdon, J

et al. for their study on Frizzleds act as dynamic pharmacological entities Marina Casiraghi, Robert J

molecules which initiate a neuronal response that drives odorant discrimination and perception (Young J.

PMID: 38378098 Curated by Sumit J. Bandekar with help from Nathan Zaidman and Abhishek K. Singh

Chakit Arora, J Silvio Gutkind, and Francesco Raimondi for their work on The landscape of cancer-rewired

N-termini that mediate ligand binding and signaling (Bannert N et al. 2001; Casarosa P et al. 2005; Gao J

GPCR Team This Week’s Highlights: Congratulations to Andrew Tobin for an incredible week filled with

Industry News X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market Andrew

Andrew Hopkins, Exscientia's CEO, will speak at the University of Chicago's Distinguished Seminar Series

for substance use disorders Superluminal Medicines Launches to Drug Protein Conformations in a Flash Andrew

DyNAbind Announce Milestone Achievement in Collaboration to Enable DEL for Membrane Proteins Professor Andrew

computational antibody drug discovery platform Antiverse identifies therapeutic antibodies targeting GPCRs CEO Andrew

Morgan Healthcare Conference Andrew Hopkins appointed CBE by HM King Charles III Voyager Therapeutics

Sosei Heptares’ Partner, Pfizer, Progresses Its GLP-1 Receptor Agonist PF-06954522 into a Phase 1 Trial Andrew

receptor as a therapeutic target for substance use disorders Leigh Walker , Christopher Langmead , Andrew